Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Myocardial infarction is a common perioperative complication, and blood flow restoration causes ischemia/reperfusion injury (IRI). Dexmedetomidine (DEX) pretreatment can protect against cardiac IRI, but the mechanism is still insufficiently understood.
Methods: In vivo, myocardial ischemia/reperfusion (30 minutes/120 minutes) was induced via ligation and then reperfusion of the left anterior descending coronary artery (LAD) in mice. Intravenous infusion of 10 μg/kg DEX was performed 20 minutes before ligation. Moreover, the α2-adrenoreceptor antagonist Yohimbine and STAT3 inhibitor Stattic were applied 30 minutes ahead of DEX infusion. In vitro, hypoxia/reoxygenation (H/R) with DEX pretreatment for 1 hour was performed in isolated neonatal rat cardiomyocytes. In addition, Stattic was applied before DEX pretreatment.
Results: In the mouse cardiac ischemia/reperfusion model, DEX pretreatment lowered the serum creatine kinase-MB isoenzyme (CK-MB) levels (2.47 ± 0.165 vs 1.55 ± 0.183; P < .0001), downregulated the inflammatory response ( P ≤ .0303), decreased 4-hydroxynonenal (4-HNE) production and cell apoptosis ( P = .0074), and promoted the phosphorylation of STAT3 (4.94 ± 0.690 vs 6.68 ± 0.710, P = .0001), which could be blunted by Yohimbine and Stattic. The bioinformatic analysis of differentially expressed mRNAs further confirmed that STAT3 signaling might be involved in the cardioprotection of DEX. Upon H/R treatment in isolated neonatal rat cardiomyocytes, 5 μM DEX pretreatment improved cell viability ( P = .0005), inhibited reactive oxygen species (ROS) production and calcium overload (both P ≤ .0040), decreased cell apoptosis ( P = .0470), and promoted STAT3 phosphorylation at Tyr705 (0.102 ± 0.0224 vs 0.297 ± 0.0937; P < .0001) and Ser727 (0.586 ± 0.177 vs 0.886 ± 0.0546; P = .0157), which could be abolished by Stattic.
Conclusions: DEX pretreatment protects against myocardial IRI, presumably by promoting STAT3 phosphorylation via the α2-adrenoreceptor in vivo and in vitro.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10319249 | PMC |
| http://dx.doi.org/10.1213/ANE.0000000000006487 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Astragaloside IV Pretreatment Alleviates Pulmonary Ischemia-Reperfusion Injury via the TLR4/MyD88/NF-κB p65 Pathway in Rats.
Phytother Res
September 2025
Department of Pharmaceutical Engineering, South China Agricultural University, Guangzhou, Guangdong, China.
Background and aim Our previous study confirmed that ASIV can protect the lung from ischemia-reperfusion injury. The aim of this study was to determine whether ASIV attenuates PIRI by inhibiting the activation of the TLR4/MyD88/NF-κBp65 pathway. Experimental procedure In vitro, the protection of ASIV, TAK-242, NAC, and DEX to OGD/R-induced cell injury was compared.
View Article and Find Full Text PDFSingle-Cell RNA-Seq Revealed the Immune Microenvironment Reprogramming by Dexmedetomidine Treatment in Ischemic Stroke.
Mol Neurobiol
August 2025
Department of Anesthesiology, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200336, China.
Prior studies have indicated that the neuroprotective effects of dexmedetomidine (DEX) in cerebral ischemia, yet its mechanisms remain elusive. Using multi-omics approaches (RNA-seq, metabolomics, and single-cell RNA-seq), we discovered that DEX pretreatment significantly reduced cerebral infarct volume and improved neurological function in middle cerebral artery occlusion (MCAO) mice compared to PBS controls. Single-cell analysis revealed that DEX preserved microglial phagocytic function via metabolic regulation, leading to reduced microglial apoptosis and attenuated immune dysregulation-including decreased chemotactic neutrophils, B cells, and antigen-presenting fibroblasts.
View Article and Find Full Text PDFRemimazolam and dexmedetomidine prevent cognitive decline by affecting lipopolysaccharide-induced brain injury in mice: Possible involvement of the vagus nerve pathway.
Biomed Res
July 2025
Department of Anesthesiology and Critical Care Medicine, Hokkaido University Graduate School of Medicine, Sapporo, Japan.
Sepsis-associated encephalopathy (SAE) is a critical neurological complication of sepsis with limited therapeutic options. This study investigated the neuroprotective potential of remimazolam (REMI) and dexmedetomidine (DEX) in a lipopolysaccharide (LPS)-induced murine model of SAE. We assessed cognitive function via trace fear conditioning, hippocampal CA3 neuronal integrity, neuroinflammatory markers (TNF-α, IL-6, IL-1β), blood-brain barrier (BBB) permeability through hippocampal albumin levels, and lung Netrin-1 expression as an indicator of vagus nerve pathway activity.
View Article and Find Full Text PDFBreaking Tumor Chemoresistance via METTL3 Regulation Enhanced by Sequential Delivery of Dexamethasone.
ACS Appl Mater Interfaces
August 2025
Department of Pharmaceutics, College of Pharmaceutical Sciences, Soochow University, Suzhou 215123, China.
The frequent occurrence of chemoresistance in breast tumors remains a challenge to achieving satisfactory therapeutic efficacy, and a smart drug delivery system with flexible properties is urgently needed to achieve an all-in-one combination anticancer therapy. In this study, an efficiency delivery system with a pH-triggered detachable PEG layer (sPEG) and a folic acid (FA)-modified cationic liposome core (FLip) is constructed for codelivering doxorubicin (DOX) and METTL3 siRNA (siMETTL3). The obtained codelivery nanoparticles (NPs), sPEG-FLip@DOX/siMETTL3, can maintain circulatory stability with minimized systemic toxicity, which is attributed to the negatively charged sPEG layer, and expose the positively charged FLip core in the weakly acidic extracellular environment to facilitate the internalization by MCF-7/ADR cells.
View Article and Find Full Text PDFThe Importance of a Pre-treatment Baseline When Screening Patients for Breast-Cancer-Related Lymphedema.
Ann Surg Oncol
July 2025
Vanderbilt University School of Nursing, Nashville, TN, USA.
Background: The PREVENT randomized clinical trial showed that bioimpedance spectroscopy (BIS) screening for subclinical breast-cancer-related lymphedema (sBCRL) detection with early intervention is associated with lower progression to chronic breast-cancer-related lymphedema (cBCRL) than tape measurement (TM). This study explores the role of a pre-treatment baseline in detecting sBCRL.
Methods: A total of 1200 patients with breast cancer were randomized for screening using L-Dex (BIS) or relative interlimb volume difference (RILVD) from TM, with 918 patients being monitored for up to 36 months.